Thursday, July 4, 2013

Ipratropium Bromide+Salbutamol Sulphate | Ipravent -S Non CFC


Ipravent -S Non CFC

Ipratropium Bromide 20 ug

Salbutamol Sulphate 120 ug

Company Name


ADCO

Therapeutic Group


A-CHOL+B2-STIM COMB.INH


Pharmaceutical form
Aerosol for Inhalation \

Package
Carton box contains aluminium metered canister with special actuator containing 200 metered inhalations and inner leaflet

Indications
"Ipratropium bromide used in treatment of obstructive airways disease,

Ipravent-S aerosol is used in patients who require more than a single bronchodilator"

Warning & Precautions
Care must be taken not to allow the aerosol to enter the eye. Should eye complications develop, treatment with miotic drops should be initiated immediately and specialist advice sought.


Product Type
Human

Dosage
"Adults : Two inhalations four times a day. The dose may be increased as' required up to a limit of inhalations per day.

Children: Not recommended for children under 12 years of age."


Adverse Reactions
The only reported side effect of significance is a slight tremor of skeletal muscles which occurs in some patients . less frequent are tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients, Treatment with nebulizer ipratropium bromide has resulted in urinary retention in elderly men especially, those with prostatic hypertrophy . Potentially serious hypocalcaemia may result from beta-agonist therapy .

Contra Indications
Ipravent-S is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine or its derivatives.

Drug Interactions
Beta-adrenergics, xanthine derivatives and corticosteroids may enhance the effect of Ipravent-S the concurrent administration of other beta-mimetics systemically absorbed anticholinergics and xanthine derivatives may increase the side effects .

5 EgyDrug Index: Ipratropium Bromide+Salbutamol Sulphate | Ipravent -S Non CFC Ipravent -S Non CFC Ipratropium Bromide 20 ug Salbutamol Sulphate 120 ug Company Name ADCO Therapeutic Group A-CHOL+B2-STI...

No comments:

Post a Comment